Nelipcpimut-S

Product Name: Nelipcpimut-S

Form: Free base

CAS No: 160212-35-1

Molar Mass: 995.21

Chemical Formula: C50H78N10O11

Synonyms: Neuvax

Storage: Store at -20℃

Sequence: KIFGSLAFL

Target: HER2

Application:

Nelipepimut-S(CAS: 160212-35-1), a cancer vaccine, consists of a human leukocyte antigen (HLA) A2/A3 restricted HER2/neu (human epidermal growth factor receptor 2; ErbB2) nonapeptide derived from the extracellular domain of the HER2 protein. This vaccine exhibits potential immunomodulating and antineoplastic activities. Administered via intradermal injection, nelipepimut-S has the capability to stimulate a specific cytotoxic T-lymphocyte (CTL) response targeted against HER2/neu-expressing tumor cells. HER2/neu, a tumor-associated antigen and a member of the epidermal growth factor receptor family of tyrosine kinases, is frequently overexpressed in various types of tumor cells and is closely implicated in tumorigenesis. The mechanism of action of nelipepimut-S revolves around its ability to induce an immune response specifically against HER2/neu-expressing cancer cells. By targeting HER2/neu, which is often overexpressed in tumors, the vaccine aims to trigger the activation and proliferation of cytotoxic T-lymphocytes, which play a crucial role in recognizing and eliminating cancerous cells. This targeted immune response against HER2/neu-positive tumor cells can potentially halt tumor growth and lead to tumor regression. Nelipepimut-S holds promise as a therapeutic option for various cancers characterized by HER2/neu overexpression, including breast cancer and gastric cancer. Clinical studies have demonstrated its safety and efficacy in stimulating immune responses against HER2/neu-positive tumors, offering a potential avenue for improving outcomes in patients with these malignancies. Additionally, its immunomodulating properties may complement existing treatment modalities such as chemotherapy and targeted therapy, potentially enhancing overall therapeutic efficacy and patient outcomes.

Current Research:

Nelipcpimut-S (also known as Nelipepimut-S), a peptide-based immunotherapy, represents an exciting advancement in cancer treatment, particularly in the field of breast cancer. This investigational vaccine is designed to stimulate the immune system to recognize and attack cancer cells by targeting a specific peptide sequence derived from the HER2 protein, which is overexpressed in various cancers, including breast cancer.

Mechanism of Action
Nelipcpimut-S is a synthetic peptide vaccine that targets a unique epitope on the HER2 protein. HER2 (human epidermal growth factor receptor 2) is a cell surface receptor that, when overexpressed, promotes the growth and spread of cancer cells. The peptide sequence incorporated in Nelipcpimut-S is selected to trigger an immune response specifically against HER2-positive cells. The goal is to generate a robust T-cell response that identifies and destroys HER2-overexpressing tumor cells, while sparing normal cells, thereby reducing the risk of toxicity associated with traditional chemotherapy or radiation therapies.

The vaccine works by inducing the production of tumor-specific cytotoxic T lymphocytes (CTLs), which recognize and eliminate tumor cells that express the HER2 protein. Additionally, Nelipcpimut-S has been designed to activate both innate and adaptive immune responses, providing a more comprehensive approach to cancer immunotherapy.

Current Research and Development
Nelipcpimut-S is currently undergoing clinical trials to assess its safety, immunogenicity, and clinical efficacy in various cancer types, particularly HER2-positive breast cancer. Early-phase trials have shown promising results, with the vaccine demonstrating a good safety profile and the ability to induce immune responses against HER2-expressing tumors.

One notable study evaluated Nelipcpimut-S in combination with trastuzumab (Herceptin), an established monoclonal antibody therapy for HER2-positive breast cancer. The combination treatment showed enhanced anti-tumor activity, suggesting that Nelipcpimut-S may work synergistically with other HER2-targeted therapies to improve clinical outcomes. Additionally, early data from trials exploring the use of Nelipcpimut-S in other HER2-positive cancers, such as gastric and ovarian cancers, indicate potential broader applications beyond breast cancer.

Advantages of Nelipcpimut-S
One of the primary advantages of Nelipcpimut-S is its ability to harness the body's own immune system to target and destroy cancer cells with minimal off-target effects. Unlike traditional chemotherapy, which can cause significant collateral damage to healthy tissues, Nelipcpimut-S offers a more precise approach, potentially leading to fewer side effects and better quality of life for patients.

Furthermore, Nelipcpimut-S can be administered as a stand-alone therapy or in combination with other treatments, such as checkpoint inhibitors or targeted monoclonal antibodies. This flexibility makes it an attractive candidate in the evolving landscape of personalized cancer therapy.

Future Directions
As clinical trials progress, the potential for Nelipcpimut-S to become a key component of HER2-targeted immunotherapy is promising. Researchers are continuing to explore its use in combination with other immune checkpoint inhibitors to enhance its efficacy and broaden its therapeutic applications. Moreover, ongoing studies are focused on identifying biomarkers that can predict which patients will respond most effectively to the vaccine.

The long-term goal is for Nelipcpimut-S to contribute to a new generation of immunotherapies that offer durable responses with fewer adverse effects, ultimately improving survival rates and quality of life for patients with HER2-positive cancers.

Reference:

Schneble, E. J., Berry, J. S., Trappey, F. A., Clifton, G. T., Ponniah, S., Mittendorf, E., & Peoples, G. E. (2014). The HER2 peptide nelipepimut-S (E75) vaccine (NeuVax™) in breast cancer patients at risk for recurrence: correlation of immunologic data with clinical response. Immunotherapy, 6(5), 519-531.